Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according ...

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly ...

Willis bought the house in 1980 for $230,000 and began putting her whimsical designer stamp on it by painting it pink and filling it with kitschy, pop-culture treasures from the 1950s, '60s, '70s, and ...

Hong Kong's IPO wave has benefited largely from policy support from the Chinese government and optimised listing rules by ...

ANEURYSMS of the coronary arteries are decidedly uncommon. They comprise congenital, mycoticembolic, syphilitic, polyarteritis-nodosa, arteriosclerotic and dissecting types. Of these, arteriosclero ...